The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine

被引:92
作者
Attar-Lévy, D
Martinot, JL
Blin, J
Dao-Castellana, MH
Crouzel, C
Mazoyer, B
Poirier, MF
Bourdel, MC
Aymard, N
Syrota, A
Féline, A
机构
[1] CEA, Serv Hosp Frederic Joliot, DSV, DRM, F-91406 Orsay, France
[2] INSERM U334, Orsay, France
[3] Univ Paris 05, Fac Cochin Port Royal, Hop St Anne, Paris, France
[4] Hop Bicetre, Le Kremlin Bicetre, France
关键词
serotonin receptors; positron-emission tomography; F-18]-setoperone; depression; clomipramine;
D O I
10.1016/S0006-3223(98)00007-9
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Changes in serotonin (5-HT)(2) receptor densities were reported in depression by postmortem studies and following treatment with tricyclic antidepressants in animal studies. Here, 5-HT2 receptors were studied in vivo in depressed patients. Methods: Cortical 5-HT2 receptors were investigated prospectively using positron-emission tomography and [F-18]-setoperone in 7 depressed patients, before and after at least 3 weeks of clomipramine (CMI), 150 mg daily. They were compared to 7 age-matched controls, Results: There was no significant difference between the untreated patients and the controls, except in the frontal region, where the [F-18]-setoperone specific binding was slightly lower in patients. After CMI treatment depression scares significantly improved and [F-18]-setoperone specific binding decreased in cortical regions, suggesting receptor occupancy and/or receptor regulation, by CMI, however no clinical score correlated with the 5-HT2 receptor measurements either in the untreated or in the treated conditions. Conclusions: These data substantiate the view that tricyclic antidepressants such as clomipramine significantly interact with cortical 5-HT2 serotoninergic receptors in actual therapeutic situations. (C) 1999 Society of Biological Psychiatry.
引用
收藏
页码:180 / 186
页数:7
相关论文
共 49 条
[1]  
ARANGO V, 1990, ARCH GEN PSYCHIAT, V47, P1038
[2]   COMPARISON OF 3 F-18-LABELED BUTYROPHENONE NEUROLEPTIC DRUGS IN THE BABOON USING POSITRON EMISSION TOMOGRAPHY [J].
ARNETT, CD ;
SHIUE, CY ;
WOLF, AP ;
FOWLER, JS ;
LOGAN, J ;
WATANABE, M .
JOURNAL OF NEUROCHEMISTRY, 1985, 44 (03) :835-844
[3]  
ARORA RC, 1989, AM J PSYCHIAT, V146, P730
[4]  
BARON JC, 1985, CEREBRAL BLOOD FLOW, P471
[5]  
BAXTER LR, 1989, ARCH GEN PSYCHIAT, V46, P243
[6]   SEROTONIN 5-HT2 RECEPTOR-BINDING ON BLOOD-PLATELETS AS A STATE DEPENDENT MARKER IN MAJOR AFFECTIVE-DISORDER [J].
BIEGON, A ;
ESSAR, N ;
ISRAELI, M ;
ELIZUR, A ;
BRUCH, S ;
BARNATHAN, AA .
PSYCHOPHARMACOLOGY, 1990, 102 (01) :73-75
[7]  
BLACKSHEAR MA, 1982, J PHARMACOL EXP THER, V221, P303
[8]   LOSS OF BRAIN 5-HT(2) RECEPTORS IN ALZHEIMERS-DISEASE - IN-VIVO ASSESSMENT WITH POSITRON EMISSION TOMOGRAPHY AND [F-18] SETOPERONE [J].
BLIN, J ;
BARON, JC ;
DUBOIS, B ;
CROUZEL, C ;
FIORELLI, M ;
ATTARLEVY, D ;
PILLON, B ;
FOURNIER, D ;
VIDAILHET, M ;
AGID, Y .
BRAIN, 1993, 116 :497-510
[9]   A METHOD FOR THE INVIVO INVESTIGATION OF THE SEROTONERGIC 5-HT2 RECEPTORS IN THE HUMAN CEREBRAL-CORTEX USING POSITRON EMISSION TOMOGRAPHY AND F-18 LABELED SETOPERONE [J].
BLIN, J ;
SETTE, G ;
FIORELLI, M ;
BLETRY, O ;
ELGHOZI, JL ;
CROUZEL, C ;
BARON, JC .
JOURNAL OF NEUROCHEMISTRY, 1990, 54 (05) :1744-1754
[10]   BLOOD CEREBROSPINAL-FLUID AND BLOOD-BRAIN BARRIERS IMAGED BY F-18 LABELED METABOLITES OF F-18 SETOPERONE STUDIED IN HUMANS USING POSITRON EMISSION TOMOGRAPHY [J].
BLIN, J ;
CROUZEL, C .
JOURNAL OF NEUROCHEMISTRY, 1992, 58 (06) :2303-2310